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The human small intestine is the site of digestion and absorption of major macro and 
micronutrients. Any abnormality which affects this part of bowel may lead to nutritional 
deficiencies as well as malabsorption syndrome. An important cause of malabsorption syndrome 
is Small Intestinal bacterial Overgrowth (SIBO).
 1,2,3,4
   
The bacterial count is extremely low in the stomach and small intestine. The normal count in 
stomach is 10
2
-10
3
 CFU/ml, in duodenum is 10
3
 CFU/ml, in jejunum the count is < 10
4 
CFU/ml 
and in ileum it’s upto 107-109 CFU/ml.  
SIBO (small intestinal bacterial overgrowth) is defined as increased bacterial counts in the 
proximal small bowel ( jejunum and ileum). It is also defined as the replacement of normal small 
bowel bacteria with the colonic bacteria. SIBO is diagnosed by jejunal aspiration (gold standard) 
and various breath tests ( Hydrogen breath tests, C
14
 breath tests, lactulose breath tests, methane 
breath tests etc. )
5,6 
 The clinical manifestations of SIBO may range from asymptomatic stage to 
malabsorption syndrome. 
Chronic pancreatitis has been defined as a clinical condition associated with morphological 
(fibrosis/calcification) of pancreas and/ or functional  (exocrine and endocrine) insufficiency of 
the pancreas.
 7,8
  SIBO has been reported in chronic pancreatitis and may be due to drugs (Proton 
pump inhibitors / analgesics), deficiency of pancreatic enzymes, impaired small bowel motility 
or surgery. 
13
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The literature regarding SIBO in chronic pancreatitis  is meagre and conflicting, with the recent 
literature contemplating  that SIBO is uncommon in Chronic pancreatitis.
9,10,14  
 Conflicting 
reports on prevalence of SIBO could be attributed to absence of population based prevalence 
studies as well as non utilization of gold standard (jejunal aspirate culture) for diagnosing SIBO. 
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                             AIMS                                                                                   
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1. To determine the frequency of SIBO (Small intestinal bacterial overgrowth) in chronic 
pancreatitis. 
2. To evaluate the sensitivity and specificity of GHBT (Glucose Hydrogen Breath Test) in SIBO 
(Small intestinal bacterial overgrowth) by comparing it to jejunal aspirate culture (Gold 
standard). 
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Study Design: 
Observational, cross-sectional, prospective and a pilot study.                                                                                                                       
Setting 
- Tertiary care centre in South India with a total bed intake of 2400 patients. 
-  Patients were recruited from Gastroenterology OPD and Pancreatic Biliary clinic. 
- The duration of the study was from August 2011 to December 2012. 
- The study was approved by the Institutional Ethics and Research Review Board. 
 
Inclusion Criteria: 
1. Adults between the ages of 18 – 60 years. 
2. Diagnosed as Chronic Pancreatitis, criteria defined as later. 
Exclusion criteria  
1. Age < 18 years and > 60 years 
2. Patients who had received any antibiotics in last 3 months. 
3. Patients who were on PPI’s (proton pump inhibitors) over the last 2 weeks. 
4. Patients who were on pancreatic supplements for at least 2 weeks before recruitment. 
8 
 
5. Patients who underwent any upper abdominal surgery including a pancreatic or gastric 
surgery. 
6. Patients who had any radiation to the small bowel. 
7. Patients with upper GI malignancies. 
8. Patients with diverticulosis of the small bowel. 
9. Pregnancy 
10. Patients who refused to give a valid consent. 
 
Diagnosis of chronic pancreatitis:  
Chronic pancreatitis was diagnosed on basis of history which was suggestive of pancreatic pain 
supported by laboratory parameters as well as radiological imaging (USG abdomen, CECT 
abdomen, MRCP or EUS). The radiological parameters on USG abdomen, CECT abdomen, 
MRCP diagnostic of chronic pancreatitis were dilated pancreatic ducts (major or minor), 
pancreatic calcifications (ductal or parenchymal), atrophy or enlargement of the gland, irregular 
gland margins, changes in the parenchymal echotexture. The EUS criteria diagnostic of chronic 
pancreatitis (parenchymal and ductal) were also used for the diagnosis. 
After recruiting the patient for the study, a detailed history was taken regarding total duration of 
symptoms of dyspepsia, pain abdomen and symptoms to suggest diabetes or steatorrhoea. The 
9 
 
duration of each symptom was recorded in detail. The socio economic status was recorded 
according to the modified Kuppuswamy scale.
15 
All patients had the following investigations done as per protocol for chronic pancreatitis at our 
centre – tests to determine etiology of chronic pancreatitis, endocrine dysfunction (blood sugars), 
exocrine dysfunction (72 hour stool fat) and nutritional status (BMI, Total protein/ albumin, 
Vitamin B12, folic acid). Imaging studies – USG abdomen, CECT abdomen, MRCP or EUS were 
also performed. 
 
Determination of Small Intestinal Bacterial Overgrowth 
 a. Jejunal aspirate culture 
b.. Glucose Hydrogen breath Test 
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Jejunal aspirate culture 
Method of jejunal aspiration 
Requirements: 
A. Endoscope – Olympus GIF 150 series (manufactured at Japan), a paediatric colonoscope 
Olympus PCF 150 series. 
B. A sheathed tube specially designed for this study- A Wilson Cook  sclerotherapy needle 
was converted into aspiration needle after it’s needle tip and outer tube were cut  at it’s 
distal end, the outer tube being at least 2 cm shorter than it’s inner tube. 
C. Culture tubes and culture media for aerobic and anaerobic bacterial culture. 
Technique for Obtaining Jejunal Juice for Culture: 
1.  After an overnight fast, the patients underwent  jejunal intubation using an endoscope. 
Topical Anaesthesia was applied prior to the procedure. Initially a paediatric colonscope was 
used. The endoscope was advanced to at least 10 cm beyond the DJ flexure and the position 
confirmed by fluoroscopy.  When the scopist was confident of reaching jejunum with a 
gastroscope,  jejunal intubation was performed with  a  gastroscope. For initial intubation of the 
jejunum, the patients were sedated with midazolam. But later on it was stopped, as the patients 
experienced more discomfort in the post procedure period  
11 
 
2.  After intubating the jejunum (at least 10cm beyond the DJ flexure), a specially designed 
sheathed tube for aspiration was introduced (Modified sclerotherapy needle, Cook medical). The 
tip of the needle was cut and the outer sheath was cut at least 2-3 cms shorter than the inner tube. 
A rubber stooper was placed at the tip of the outer tube after washing and was  in the same 
position during sterilization. This was to prevent contamination of the inner tube when passed 
through the biopsy channel of the endoscope (Figure 1). 
3. After the tube was introduced into the jejunum, through the endoscope biopsy channel, the 
rubber stopper at the tip of the outer tube was dislodged when the inner tube being pushed out 
(Figure 3). 
4.  A EUS (endoscopic ultrasound) suction needle was used to aspirate the jejunal contents .The 
endoscopist, the assisting nurse and the technician used strict aseptic precautions while obtaining 
the sample. As soon as 2-3 ml of jejunal juice was aspirated into the sterile syringe, the inner 
tube was withdrawn into outer tube and the endoscope was withdrawn with the tube in situ 
(Figure 2) 
12 
 
                     
Figure 1: Tube with rubber stopper at the tip       Figure 2: Base of the tube                     Figure3: Rubber dislodged with the inner tip out 
 
5. The aspirate was then divided into 3 portions and sent for aerobic culture, anaerobic culture 
and a third portion stored for future reference. 
 
13 
 
    
 
Culture technique: 
1.  50µL of the diluted (all four serial dilutions) and non-diluted samples was spread on the 
corresponding aerobic and anaerobic media plates. 
2. Aerobic culture media used were – MacConkey’s media, Nutrient agar, Salmonella 
Shigella agar (SS agar) and Blood agar; the diluted sample was plated on all these media 
for 24 hours at 37   c. 
3. The anaerobic media used were – Gut microbial medium, MRS agar and Bifidobacterium 
agar at 37   C for 24 -48 hours in 80% nitrogen and 20% carbon dioxide (CO2). 
Jejunal 
Aspirate 
Aerobic  Anaerobic 
Storage for 
future 
reference 
14 
 
4. The culture media were first observed after 24 hours of incubation for any growth 
followed by every 12 hourly thereafter to look for colonies and further dilutions if 
required.  
5. Dilutions from 10-1 to 10-4 were generally performed. After a 24- to 48 h incubation at 
 
 37˚C, colonies were counted. The choice of the last dilution was decided after the results 
 
 of direct examination. 
A CFU (colony forming unit) of > 10
5
 /ml was diagnosed as SIBO. 
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Glucose Hydrogen Breath Test (GHBT) 
Principle and technique:  
The source of hydrogen in humans is the metabolism of carbohydrates by the native bacteria in 
the large intestine. In patients with SIBO, glucose that reaches the jejunum is metabolized by the 
bacteria in the proximal small bowel. The metabolized glucose produces hydrogen which 
diffuses into the systemic circulation, and about 20% of the hydrogen gas produced is expired 
from the lungs  into the air.
16 
In GHBT, glucose is consumed by the patient at a predefined dose depending upon body weight 
of patient with a minimum of  50 gram to a maximum of 75 gram. The air is expired by the 
patient is collected via a mouth piece which is then connected to hydrogen breath meter 
(manufacturer Bedfont, UK). The machine detects the breath hydrogen and expresses the results 
in parts per million (ppm) of hydrogen in the expired air. In normal individuals the expired air 
contains hydrogen levels of < 20 ppm in fasting state and the rise after glucose is not more than 
12 ppm above the baseline. 
Positive test:  Baseline breath hydrogen level  above 20 ppm or a peak in breath hydrogen level 
after glucose which is 12 ppm above the baseline level. 
 
16 
 
Precautions:    
 1. The patients should be fasting overnight. 
 2. The patients should avoid smoking. 
 3. The patients should not exercise prior to the test. 
4. The patients should avoid fermentative diets ( high fiber diet), atleast the night prior to the 
breath test. 
Method: 
a. After an overnight fast, the patient was asked to do a mouth gargle with chlorhexidine 
followed by a baseline expired breath, which was recorded as baseline or zero minute. 
b. Then patient was given 50 gm / 75 gm of glucose dissolved in fresh water (250 ml). 
c. Then the patient was instructed to given breath samples every 20 min till 120 minutes. 
d. The results were recorded and plotted on a graph and report given as negative GHBT or 
Positive GHBT (Figure 4).  
 
17 
 
:  
Figure 4:  Positive glucose hydrogen breath test 
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 STATISTICAL METHODS 
The categorical data were compared using the Fisher exact test. 
The continuous data were compared using Mann Whitney U test as the data did not have normal 
distribution. 
The SPSS 16 version of the software was used to calculate the data. 
As the study was a pilot study, all patients who were diagnosed with chronic pancreatitis and 
fulfilled the inclusion and the exclusion criteria were recruited. Since there were limited 
finances, the study could not be changed into a prevalence study and was continued as a pilot 
study. 
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Introduction 
SIBO (small intestinal bacterial overgrowth) is characterized by excessive growth of bacteria in 
the small intestine especially in the proximal small bowel. Characteristically the normal flora of 
the proximal small bowel is gram positive aerobes but in SIBO it is gradually replaced by gram 
negative aerobes and anaerobes.
16
 In the tropics, the normal small bowel flora has been defined 
from 10
5
 – 107 CFU’s/ml in jejunal fluid. The recent literature has shown that bacterial CFU’s of 
10
5
 /ml can also be accepted for the diagnosis of SIBO. 
17,18
 
The prevalence of SIBO (small intestinal bacterial overgrowth) in a normal healthy adult 
population is difficult to be defined as there is lack of data in the literature and non utilization of 
the gold standard for this purpose in the studies. There have been multiple studies which have 
utilized breath tests for the prevalence of SIBO in the normal population and among them SIBO 
(small intestinal bacterial overgrowth) ranges from 0 to 13 % when GHBT (glucose hydrogen 
breath test) was utilized as compared to LHBT (lactulose hydrogen breath test) which 
demonstrated a prevalence of 21% in the general population and when 
14
C-d xylose was used it 
showed an overall prevalence of 0-35% of SIBO in the normal study population.
19
 
There are multiple etiologies of SIBO,  as shown in table 1 : 
 
21 
 
TABLE 1: ETIOLOGY OF SIBO 
Physiological Old age,
23,24
 Achlorhydria
25,26
 
Small intestine stasis 
  1.Abnormal motility 
 
   
 
 
 
 
2. Diverticulosis
36
 
 
1.1 Neuropathy including Diabetes mellitus.27,28,29 
1.2 Scleroderma30 
1.3 Amyloidosis 
1.4 Hypothyroidism 
1.5 Idiopathic intestinal Pseudoobstruction31,32 
1.6 Radiation33,34 
1.7 IBD especially Crohn’s disease35 
Post surgical
37,38
 Gastrojejunostomy, Pancreatic resection & IC valve resection 
Strictures (Crohn’s disease, radiation and surgery). 
Intestinal Fistulas Gastrocolic 
Small bowel fistulas due to multiple etiologies 
Multifactorial 1. CLD (chronic liver disease)
39,40,41
 
2. IBS (irritable bowel syndrome)42,43,44 
3. Celiac disease45,46 
22 
 
4. Chronic pancreatitis14 
5. Immune deficiency syndromes including HIV47,48 
6. CKD (chronic kidney disease) 
7. Tropical sprue17,49 
8. Rare: Farsenoid receptor alterations50 
 
 
Pathogenesis of SIBO: 
The development of SIBO is seen due to multiple etiologies and their interactions, but when 
taken into isolation two factors which contribute more than other factors are a. altered small 
intestinal motility and b. decreased gastric acid production.  
The protective factors which play role in prevention of SIBO (small intestinal bacterial 
overgrowth) are: 
i. Protective mucus lining of the small bowel mucosa. 
ii. Various enzymes in the secretions (pancreatic, biliary and intestinal) which are 
present in the intestinal lumen. 
iii. Commensal flora which plays a protective role for e.g Lactobacilli, Bifidobacteria.  
23 
 
iv. Intact IC (ileocecal) valve.52,53 
The anaerobic bacteria which are predominant in SIBO lead to a state of nutritional deficiency 
by utilizing cobalamin which in turn leads to decreased levels of vitamin B12, which may lead to 
various clinical manifestations ranging from asymptomatic macrocytic anemia to neuropathy and 
subacute degeneration of the spinal cord.  
54
 There is associated malabsorption of fat soluble 
vitamins except vitamin K which is produced in excess by the overgrowing bacteria. At the 
microscopic level there is alteration in the brush border enzymes and which may further add to 
malabsorption syndrome.
55 
There are morphological and functional alterations in the small intestinal mucosa in chronic 
pancreatitis. There can be enteritis with loss of mucosal enzyme activity which may lead to 
decreased absorption, decreased local immunity and bacterial overgrowth.
 56
 
Methods of diagnosis of SIBO: 
The gold standard for diagnosis of SIBO (small intestinal bacterial overgrowth) is jejunal 
aspiration. Bhat and colleagues defined a CFU of 10
7
/ ml as normal in tropics.
17
 
There are multiple techniques of diagnosis of SIBO (small intestinal bacterial overgrowth) and 
these can be divided in two types:  
a. Invasive and  
24 
 
b. Non invasive. 
Invasive includes: Jejunal aspiration methods such as  
1. Fluoroscopic intubation of the jejunum.
20,21,22
 
2. Endoscopic mucosal brushings
57
 
3. Endoscopic mucosal biopsies.
58,59
 
4. Endoscopic jejunal aspiration.
21
 
There are various drawbacks of this techniques are: 
1. These are invasive methods. 
2. There are high chances of contamination of the aspirate with oro pharyngeal or gastric or 
duodenal secretions. 
3. The culture based techniques have certain limitations in addition to being invasive, which 
are  
(i) Low reproducibility – multiple studies have shown that the cultures have 
diagnostic yield of < 40%.
60
 
(ii) The period of incubation and final results are obtained may take 48 hours to few 
days. 
25 
 
A recent study done by Chandra et al showed that endoscopic biopsy culture may be as good as 
jejunal aspirate in Indian population.
59 
The study population included 48 pairs of fluid and 
mucosal biopsies, in 45 pairs they were able to obtain both jejunal biopsy and as well as jejunal 
fluid. The study concluded that the jejunal mucosal biopsy can be used as an alternative to 
jejunal aspiration for assessing jejunal microflora. 
Non invasive methods include:  
a. Breath tests 
b. Radiological methods including a 1H-NMR spectroscopy- 41 and various imaging techniques 
of the small bowel. 
Breath Tests: 
The breath tests came into existence due to drawbacks of the jejunal aspirate as described earlier. 
These are indirect ways of estimating SIBO (small intestinal bacterial overgrowth) by means of 
estimating level of certain end products of substrates in the expired air produced by metabolism 
by small bowel or large bowel bacteria. 
Principle of breath tests: The source of hydrogen in humans is the metabolism of carbohydrates 
by the native bacteria. These complex and simple carbohydrate metabolism and absorption is 
deficient in a group of patients and this leads to development of malabsorption. When this 
26 
 
associated with proximal migration of the colonic bacteria into the small bowel or there is 
overgrowth of native bacteria, this leads to SIBO (small intestinal bacterial overgrowth). 
This hydrogen which is produced after the metabolism is very quickly absorbed into the blood 
and is expired in the air. This can be easily picked up and measured in the expired air utilizing 
the breath tests. 
 
 
Figure 5 
27 
 
 
There are various types of breath tests and there sensitivity and specificity ranges from 30-80% 
and 50-95% respectively.
61,62 
TABLE 2: TYPES OF BREATH TESTS WITH THEIR SENSITIVITIES AND SPECIFICITY 
Test / reference Sensitivity (%) Specificity (%) 
Glucose Hydrogen breath Test 
Kalin and Wang (1988)
63
 
Corraza etal (1990)
64
 
Ghoshal et al (2006)
65
 
 
93 
62 
44 
 
78 
83 
80 
Lactulose hydrogen Breath tests 
Ghoshal et al (2006)
65
 
Rhodes et al (1979)
66
 
 
31 
89 
 
86 
100 
D Xylose 
King and Toskes (1986)
67
 
Lewis et al (1999)
68
 
 
95 
79 
 
100 
85 
C14 – Bile acid breath test 
King et al (1980)
69
 
 
33.3 
 
- 
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Advantages of breath tests: 
1. Simple to perform 
2.  Cheap 
3. Easily available 
4. Non invasive 
5. Does not require specially trained staff. 
6. Results are available at the end of the test. 
Disadvantages of the breath test: 
1. Low sensitivity 
2. In the general population about 15 % patients are methane producers and these patients 
will not be diagnosed with conventionally used Hydrogen breath tests.
70
 
3. The results depend upon the patient related factors which includes smoking, consumption 
of high fiber prior to the test, exercise during the test etc. 
4. The slow and rapid transit of the small bowel may alter the interpretation of the results. 
The other types of the breath tests: 
1. Lactulose hydrogen breath test 
2. Lactose hydrogen breath tests 
29 
 
3. Rice breath test 
4. C14 D xylose breath test 
5. Cholyl – PABA test 
6.  Methane breath test 
7. 14C-Glycocholic acid breath test 
Lactulose Hydrogen breath test: The principle of the glucose and lactulose hydrogen breath 
test is similar, in this test a non absorbable starch that is metabolized in colon by the action of the 
colonic bacteria and it produces a late peak in the breath analysis.
71
 It has been utilized in 
estimating OCTT (oro cecal transit time). 
Lactose Hydrogen breath test: It detects lactose malabsorption and it is shown in previous 
study by Reis et al in 1999 that the children who had Lactose malabsorption had no statistical 
relationship with SIBO (small intestinal bacterial overgrowth) and it was noted in 7.2% 
children.
72
 
14
C-xylose and 
13
C-xylose breath tests: These tests detect a labeled CO2 that is produced by the 
metabolism of a labeled substrate in the proximal small bowel with the action of bacteria. The 
substrate used is d-xylose and labeled carbon is either C-13 or C-14. A study was done in 2000 
by Stotzer et al, which compared radio labeled d-xylose with glucose hydrogen breath test and 
30 
 
found that and found that the sensitivity of the GHBT was 58% with a specificity of 86% 
respectively.
73,74
 
Cholyl PABA: It has been described in literature but it is not able to distinguish between SIBO 
and malabsorption. 
14
C-glycocholic acid breath test: It is one of the earliest used breath test in SIBO. It is not used 
these days due to it’s low specificity and sensitivity and unable to distinguish between SIBO and 
malabsorption.
75 
 
1H-NMR spectroscopy for SIBO (small intestinal bacterial overgrowth): A study was done 
in 2006 in India which used the proximal small bowel aspirate of patients with malabsorption 
syndrome who had SIBO (small intestinal bacterial overgrowth) and who did not had SIBO 
(small intestinal bacterial overgrowth). The aspirate was analyzed using a spectrometer (NMR). 
The study showed that the patients with SIBO (small intestinal bacterial overgrowth) had 
increased quantities of bile acid, cholesterol, lactate and acetate in their intestinal aspirate. The 
acetate had a statistical positive correlation with SIBO (small intestinal bacterial overgrowth).
76 
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Chronic pancreatitis: 
Definition – Chronic pancreatitis is a clinical condition associated with fibrosis and calcification 
of pancreas and with insufficiency of both exocrine and endocrine parts of the pancreatic gland. 
A national prospective study in India showed that the most common etiology of chronic 
pancreatitis is idiopathic (60.2%) and alcohol related (38.7%) when compared to US where the 
most common etiology for chronic pancreatitis is alcohol.
77
 
The pancreatitis has been classified by various classifications but the classifications which are 
utilized more commonly are two classifications a. TIGAR-O and b. M-ANNHEIM.
78,79 
In the year 2007 Schneider A et al from Germany classified chronic pancreatitis as M-
ANNHEIM (multiple risk factors – alcohol, nicotine, nutritional factors, hereditary, efferent duct 
factors, immunological and miscellaneous factors) which included the clinical stage (clinical 
symptomatic and asymptomatic stage), the etiology and severity of the disease ( from clinical 
minor disease to exacerbated disease). They utilized a standardized scoring system which 
included the symptoms of pain and requirement of analgesics according to the WHO step ladder 
as well as imaging and treatment modalities opted for the management of chronic pancreatitis. 
Finally the chronic pancreatitis was graded according to the severity of the disease index and it 
had a range from minor to exacerbated disease index. A score was given which had a range from 
0 to > 20 points.
80,79
 
32 
 
In the year 2001 Etemad et al had provided another classification of chronic pancreatitis named 
as TIGAR-O ( toxic-metabolic, idiopathic, genetic, autoimmune, recurrent & acute severe 
pancreatitis and obstructive) which was based primarily upon the etiology of chronic 
pancreatitis. However this classification when compared to M-ANNHEIM, did not include the 
clinical symptoms, the management and prognosis of the disease depending upon the overall 
severity of the disease. However when compared to M-ANNHEIM classification, it was more 
simple and easily applicable to the clinical practice.
78 
Chronic pancreatitis and SIBO: 
Etiology: 
1. PPI (proton pump inhibitor) usage 
2. Drugs :- Analgesics 
3. Alcohol14 
4. Gastric and pancreatic surgery 
5. Advanced age 
6. Pancreatic calcification14 
 
33 
 
 
 
SIBO is considered to be present in chronic pancreatitis patients, when they don’t respond to the 
usual treatment and have malabsorption despite an adequate pancreatic enzyme replacement. 
Trepsi et al in1999 showed that SIBO is more frequent in chronic pancreatitis and pancreatic 
insufficiency particularly who underwent gastroduodenal surgery. They used glucose hydrogen 
breath test for diagnosis of SIBO.  However in this study a small group of patients with chronic 
pancreatitis were taken (n=35). The patients of chronic pancreatitis with exocrine insufficiency 
and gastroduodenal surgery were compared with patients with gastroduodenal surgery alone 
using a glucose hydrogen breath test. The study found that SIBO was seen in 34 % of patients 
with chronic pancreatitis and exocrine insufficiency when compared to control group which had 
GHBT positivity of 21 % only. The SIBO was more likely to be present if the etiology of chronic 
SIBO IN 
CHRONIC 
PANCREATITIS 
ETIOLOGY 
ALCOHOL 
MORPHOLGY 
CALCIFICATION 
INSUFFICIENCY 
DRUGS 
PPI’S/ 
ANALGESICS 
OTHERS 
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pancreatitis was alcohol, there were associated pancreatic calcifications, there was associated 
gall stones and in patients who had a gastric resection. The study found that the diarrhoea was 
the only statistically significant factor in patients with chronic pancreatitis patients, when 
compared with the control group. The patients diagnosed with SIBO were given a non 
absorbable antibiotic rifaximin 400 mg thrice a day for one week every monthly.
14
 
Mancilla et al also showed that the SIBO was more common in patients with chronic pancreatitis 
and may be the cause for persistent symptoms despite adequate treatment with pancreatic 
enzymes. This study used laculose hydrogen breath test for the diagnosis of SIBO. The study 
found that 92% patients with chronic pancreatitis had SIBO when compared to 7% in controls 
with a significant p value of <0.001. The study concluded that proper diagnosis and treatment of 
SIBO may help in improvement in symptoms and life .
81 
Lambacke et al in 1985 used 14C-cholylglycine breath test in patients with chronic pancreatitis 
and found that 40 % patients had SIBO. This may clinically manifest as diarrhoea and 
steatorrhoea, which may resolve after pancreatic enzyme supplementation.
83
 
Grigoreva et al in the year 2010 established that SIBO is seen in majority of patients with 
chronic pancreatitits. The samples used in these patients were from the duodenum and found that 
there was association between duodenal inflammation, lymphangiectasia and SIBO with chronic 
pancreatitis.
84
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Bode et al in 2000 hypothesized that alcohol alone without chronic pancreatitis can lead to 
increased prevalence of SIBO and which may further may lead to malabsorption. The alcohol 
may interfere with local enzymes and can affect the absorption of macro and micro nutrients in 
the small bowel.
85
 
Whereas Madsen et al in 2003 showed that SIBO may not be the factor leading to non tolerance 
of pancreatic enzyme supplementation in patients with chronic pancreatitis. They hypothesized 
that these patients can have altered small bowel permeability as well as bile acid absorption 
defect.
86 
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Baseline demographics: 
Of the consecutive 84 patients with a diagnosis of chronic pancreatitis who were initially 
screened, 36 were finally excluded from the final analysis  
The patients who were not recruited for the study: 5 patients had pancreatic tumors,7 patients had 
failed jejunal intubation, 6 patient refused to give a consent, 8 patients did not undergo either of 
the two procedures- jejunal aspirate or glucose hydrogen breath test and 10 patients had taken 
drugs either a PPI or pancreatic enzyme supplementation prior to the procedure after the 
recruitment. 
The consecutive 48 patients were included in the study.  
The duration of the study was from August 2011 to December 2012. 
Of the 48 patients enrolled, majority were males 34/48(70%), as shown in the graph. 
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                             GRAPH 1: SHOWING SEX DISTRIBUTION 
 
The patient distribution was majority from Eastern part of India followed by Tamil Nadu. 
SEX 
MALE
FEMALE
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                 GRAPH 2: SHOWING THE POPULATION DISTRIBUTION 
 
 
 
 
 
 
 
POPULATION DISTRIBUTION 
WEST BENGAL
TAMIL NADU
ANDHRA PRADESH
REST OF INDIA
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                                          PATIENT CHARACTERISTICS 
TABLE 3:  SHOWING PATIENT CHARACTERISTICS 
TOTAL PATIENTS n=48 
MALES 34 
ALCOHOL (Etiology) 29 
DIABETES MELLITUS 17 
DYSPEPSIA 41 
PAIN ABDOMEN 31 
STEATORRHOEA (SYMPTOM) 18 
BMI 19.2 
HEMOGLOBIN 12.4 ± 1.6 
ALBUMIN 4.5 ± 0.5 
B12 (μg/dl) Median 409  
FOLIC ACID (pg/ml) 8.9  ±  4 
STOOL FAT (72 HOUR) 24 patients 
RADIOLOGICAL FINDINGS 
DILATED MPD 
CALCIFICATIONS 
PSEUDOCYST 
VENOUS THROMBOSIS (PORTAL VEIN/ SPLENIC VEIN) 
DILATED CBD / IHBRD 
 
44 
38 
15 
10 
5 
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The mean age of the patients was 33.6 ± 10.4 years and the median age was 32.5 years. 
All the study patients underwent the relevant clinical and laboratory evaluation as decided by the 
treating physician. 
 
 
 
Patients recruited 
from OPD 
84 
Patients screened 
Patient available 
for final analysis 
48 
Pancreatic tumors-5 
Failed jejunal intubation-7 
Refused for consent-6 
Did not undergo both 
procedures-8 
Had taken drugs-10 
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The etiology of chronic pancreatitis was idiopathic in majority 29/48 (60 %) followed by alcohol 
in 18/48 (37.5 %).  
The most common presenting symptoms were dyspepsia and pain abdomen which were in 
41/48(85 %) and 31/48(64 %) respectively. 
The dyspepsia was present for a duration of 1-5 years in 34/41 patients. 
The pain was present for 1-5 years in 21/31 patients with mild pain in 10 patients, moderate in 18 
patients and severe pain in 6 patients respectively. 
Steatorrhoea was the presenting complaint in 8/48 (16.6%) and it’s total duration was less then 1 
year. 
The mean BMI of the patients was 19.2 and the socioeconomic status was low (modified 
Kuppuswamy scale).
15
 
A total of 17 patients were on pancreatic enzyme supplements and 18 patients were on proton 
pump inhibitors prior to recruitment for the study. These patients were successfully able to stop 
the drugs for atleast 2 weeks and were recruited for the study. 
The mean hemoglobin value was 12.4 ± 1.6 gm/ dl. 
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The mean serum albumin level was 4.5 ± 0.5 gm/ dl. 
The most common diagnostic modality for diagnosis of chronic pancreatitis was CECT abdomen 
43/48 (89 %) and two cases were diagnosed with EUS only. 
The findings on the imaging were: dilated MPD (major pancreatic duct) was noted in 44/48 
patients, the mean MPD diameter was 4.9 mm. The other most common findings were 
calcification (pancreatic parenchymal or intraductal) which was noted in 38/48 patients. The 
other findings were pseudocyst (15/48), venous thrombosis 10/48 (splenic vein thrombosis in 
8/10 and portal vein thrombosis 2/10) respectively, CBD (common bile duct) dilatation and 
IHBRD (intrahepatic biliary radical dilatation) were noted in 5/48 patients respectively. 
The mean 72 hour stool fat was 24 gm (n=34), although it could not be completed in 14 patients. 
Ten patients had pain abdomen after ingestion of fat for the test and the remaining four patients 
already had pain abdomen due to which the test could not be ordered.  
None of the patients with or without SIBO had folic acid level > 20 pg/ml and the serum vitamin 
B12 levels were low as shown by previous studies.
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The mean B12 levels were 487.2 μg / dl and the median value was 409 μg/dl, with a range of 144 
-1214 μg/dl. 
The mean folic acid level was 8.9 ± 4 pg/ ml. 
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Average M-ANNHEIM score was between 6 –10(showing medium risk), with a mean of 7 in 
patients with SIBO and 6 in patients with non - SIBO respectively. 
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Jejunal aspirate: 
The aspiration was done in all the patients and all the samples were cultured. The positive result 
was depicted by the growth of the colonies over the culture media and the serial dilutions 
required for each sample. Sixteen patients had growth of > 10
5
 cfu / ml and were diagnosed as 
SIBO (small intestinal bacterial overgrowth). 
There was mixture of organisms noted in 14 samples and the predominant organisms were 
aerobic with significant anaerobic organisms as well, as shown by the aerobic culture media.  
In 9 patient samples the predominant organisms were anaerobic with significant aerobic bacteria 
as well. The rest of the 32 patients had growth but < 10
5
 cfu  / ml. The patient samples had 
mixture of both anaerobic and aerobic organisms with most dominant being the anaerobic 
bacteria. 
Out of 32 patients with non SIBO (small intestinal bacterial overgrowth), 22 of them had 
bacterial CFU of 10
3
 – 104 / ml of the fluid. Two patients had CFU count ≤ 101 and six patients 
had CFU ≤ 102 / ml respectively. 
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TABLE 4: SHOWING COLONY FORM UNITS AND PATIENTS 
COLONY FORMING UNIT / ML (CFU) NO. OF PATIENTS 
≤ 101  2 
≤102 6 
≤ 103 13 
≤ 104 9 
≤ 105 2 
>  10
5
 16 
 
Glucose hydrogen breath test: 
The glucose hydrogen breath test was used for diagnosis of SIBO in patients of chronic 
pancreatitis. 
The technique was defined earlier in the methodology.  
The machine used was Bedfont, from UK and the amount of glucose given was 50 gram 
dissolved in 250 ml of fresh water. 
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Breath samples of all the 48 patients were collected and result was generated in form of a graph 
and a table along with the graph. The results were reported as glucose intolerant or negative for 
intolerance. 
Out of 48 patients 12 had glucose intolerance on breath testing. When compared to the jejunal 
aspirate two patients were false positive, ten were true positive and six was false negative. 
The median breath hydrogen level was 16.5 ppm in SIBO (small intestinal bacterial overgrowth)  
with a range of 4-41 ppm whereas in non-SIBO (small intestinal bacterial overgrowth)  the 
median breath hydrogen level was 5.25 ppm with a range from 1-26 ppm respectively.  
Patients with SIBO (small intestinal bacterial overgrowth): 
A total of 16 patients had SIBO (small intestinal bacterial overgrowth) with a CFU count in 
jejunal aspirate of > 10
5
/ml.  
Out of 16 patients 12 were males and 4 were females, all females with diabetes had SIBO (small 
intestinal bacterial overgrowth). 
10 patients with steatorrhoea had SIBO (small intestinal bacterial overgrowth). 
The dyspepsia was more common in patients without SIBO, however it was non significant. 
The pain as symptom was more common in patients with SIBO, it was non significant.  
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The 24 hour stool fat was more common in patients with SIBO (62%) but it was non significant. 
When imaging findings were compared between SIBO and no-SIBO, the calcification was more 
common in patients with SIBO (62%). The pseudocyst was seen slightly more common in SIBO 
(37%) versus non-SIBO (31%). 
The venous thrombosis was also seen slightly more common in patients with SIBO (25%) versus 
non-SIBO (18.6%). 
The median GHBT level was 16.5 ppm and 5.25 ppm in SIBO and non-SIBO respectively. The 
range of GHBT was 4-41 ppm and1-26 ppm in SIBO and non-SIBO respectively. 
The GHBT values were significant when compared between SIBO and non-SIBO, the p value 
was <0.001.   
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TABLE 5:  SHOWING CHARACTERISTICS OF PATIENTS WITH SIBO AND NON SIBO 
Characteristics of patients NON SIBO  SIBO  p VALUE 
PATIENTS  32  16           - 
SEX DISTRIBUTION ( MALE/  FEMALE)  24 / 8  12 / 4          NS 
ETIOLOGY ( ALCOHOL/ NON ALCOHOL)  12 / 20  6 / 10           NS 
DIABETES (PRESENT/ ABSENT)  13 / 32  4 / 16         0.35 
DYSPEPSIA ( PRESENT/ ABSENT) 28 / 32  13 / 16         0.45 
PAIN (PRESENT/ ABSENT) 18 / 32  13 / 16         0.12 
STOOL FAT (PRESENT/ABSENT) 8 / 32  10 / 16            NS 
IMAGING FINDINGS 
CALCIFICATION 
PSEUDOCYST 
VENOUS THROMBOSIS( SVT/PVT) 
 
12/32 
10/ 32 
6/ 32 
 
10/16 
6/ 16 
4/ 16 
 
      0.13 
      0.67 
          NS 
GHBT  
MEDIAN LEVEL (ppm) 
2  
5.25 
10 
16.5  
         NS 
     < 0.001 
M-ANNHEIM  6  7             NS 
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TOTAL CASES   
48 
SIBO 
 
JEJUNAL 
ASPIRATE 
POSITIVE = 16 
AEROBIC 
Species 
14 
ANAEROBIC 
species 
9 
GHBT 
POSITIVE = 10 
NON SIBO 
32 Cases 
GHBT positive= 2 
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Our study was aimed to find out the frequency of SIBO in chronic pancreatitis and also to find 
whether GHBT can be used to diagnose SIBO.  
Clinical and investigation profile of chronic pancreatitis patients was done and these were later 
on studied to find any difference between the SIBO and non-SIBO patients in the final analysis.  
It was a pilot study and only study group was included, there was no control group, as it was not 
approved by the institutional review board. 
The most common etiology for chronic pancreatitis was idiopathic as shown by the national 
survey done for etiology of chronic pancreatitis.
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SIBO was found in 1/3
rd
 patients with chronic pancreatitis. This is comparable with the literature 
available. 
There could be multiple factors which may lead to SIBO in chronic pancreatitis such as  
1. Due to decreased pancreatic enzymes especially lipase which may lead to loss of 
inhibition of growth of bacteria which leads to their overproduction.  
2. The other factor may be use of PPI’s in all most of these patients which may lead to 
decreased gastric acid production.  
3. The use of analgesics especially opioids  may lead to altered motility and stasis which 
leads to bacterial overgrowth.   
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4. The patients with gastroduodenal surgery in chronic pancreatitis also have increased 
incidence of SIBO which could be due to altered anatomy, which we did not included in 
our study. 
5. The advanced age and achlorhydria may predispose to SIBO due to loss of gastric acid 
action on the growth of the bacteria. 
 
The strength of our study was that, we utilized the gold standard for diagnosing SIBO (jejunal 
aspirate).  
Our study is the 1
st
 study published in English literature to use gold standard for diagnosing 
SIBO in chronic pancreatitis. All the previous studies have utilized breath tests for diagnosis of 
SIBO in chronic pancreatitis. 
The mean age of the patients was 42 years and predominant patients were males comprising 
more than 2/3
rd
. Most patients came from East and South India reflecting the patient population 
visiting CMC. 
Dyspepsia and abdominal pain were the most common presenting symptoms. Dyspepsia was 
more common in the non-SIBO patients whereas pain was more common in the SIBO patients 
respectively, however none of them was statistically significant. 
54 
 
Mean Hemoglobin and albumin were comparable between the two groups and for the whole 
study as well. 
Alcohol was the most common etiology and there was no difference in etiology between SIBO 
and non-SIBO. The increased incidence of SIBO among the alcoholics may be due to altered 
small bowel permeability, altered mucosal enzymes and altered small bowel motility. 
Diabetes mellitus was present in similar number between the two group of patients and all 
female diabetics were having SIBO. The onset of diabetes in chronic pancreatitis signifies 
advanced disease and more chances of developing SIBO. 
The 72 hour stool fat value was higher in SIBO patients and more patients with SIBO had 
steatorrhoea. But it was statistically non significant. The presence of steatorrhoea in chronic 
pancreatitis represents advanced disease with severe organ insufficiency which may lead to 
SIBO. 
The imaging diagnosis of chronic pancreatitis was done with CT abdomen in majority of patients 
and some findings were seen more in patients with SIBO such as pancreatic calcifications 
(parenchymal and ductal) and venous thrombosis (portal and splenic). This was also shown by 
Trepsi et al in 1999 that the prevalence of SIBO was higher in patients with chronic pancreatitis 
and there was increased association with alcohol abuse, microclacifications of pancreas, 
cholelithiasis, diabetes and diarrhea. Where as in our study, we found that alcohol abuse and 
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pancreatic calcification were more common in patients with SIBO but these were statistically 
nonsignificant when compared with non SIBO patients. The increased frequency or pancreatic 
calcifications and venous thrombosis in our study was associated with SIBO, which may be due 
to advanced and severe disease. 
The median M-ANNHEIM score was higher in SIBO than non SIBO but it was statistically non 
significant. In a recent study done in 2012, the M-ANNHEIM score in chronic pancreatitis was 
5.
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In our study we used GHBT in addition to jejunal aspirate in patients with SIBO and we tried to 
find the sensitivity and specificity of GHBT. We completed GHBT in all patients who were 
recruited in the study. The median level of hydrogen in the breath was higher in SIBO patients 
and it was significant with a p <0.0001. Ten patients who had SIBO diagnosed by jejunal 
aspirate were glucose intolerant and were correctly diagnosed by the GHBT. In six patients the 
GHBT was negative, which could be attributed to the patients being methane producers. As 
shown in literature that 15 % of patients may be methane producers and will be negative on 
GHBT . 
In two patients the GHBT was false positive and it could be related to patient factors  
a. Due to  intake of fiber or fermentative diet in previous night prior to the GHBT 
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b. Oral Bacteria which could be due to improper mouth gargle and poor oro dental hygiene. 
Although it was mandatory for all patients to avoid taking high dose carbohydrates and 
do a good mouth gargle with a disinfectant prior to giving a breath sample. 
The sensitivity of the GHBT was 62% and the specificity was 92% which is comparable to other 
studies published in literature, comparing GHBT and jejunal aspirate. Although none of them has 
compared GHBT and jejunal aspirate in chronic pancreatitis. 
45,60,61,62,63,64
 
As the table 6 shows that the number of patients recruited in these studies is small and 
comparable to our study. Only one study by Corraza et al had patient numbers more than our 
study. They utilized both lactulose and GHBT for diagnosis of SIBO in malabsorption syndrome. 
They compared the breath tests with culture and found the sensitivity and specificity of both tests 
was 62%, 68% and 83%, 84% respectively.  
A similar study was done by Ghoshal et al in 2006 from India and it showed that in a small 
number of patients, the sensitivity of the GHBT was 45% and the specificity was 80 % 
respectively, these results were comparable to our study. However our results showed a higher 
sensitivity and specificity, this could be due to more strict inclusion and exclusion criteria. For 
e.g any patient who was unsure about the intake of antibiotics in last 3 months was excluded and 
patient with intake of PPI’s and pancreatic enzyme supplementation. The reason may be due to a 
small study group of 48 patients. 
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TABLE 6 : SHOWING THE COMPARISON BETWEEN OUR STUDY AND PREVIOUS STUDIES 
Author No of 
patients 
Test Gold 
standard 
Sensitivity Specificity  
Our study 48 GHBT Culture 62% 89% 
Bauer
60
 40 GHBT CULTURE 41 80 
DONALD
61
 39 GHBT/ BABT/ 
XBT 
CULTURE 20/30/33 77/89/76 
CORAZZA
62
 77 GHBT/ LBT CULTURE 62/68 83/44 
KERLIN
63
 27 GHBT/ RICE 
BREATH TEST 
CULTURE 93/ 81 78/ 67 
GHOSHAL
45
 32 GHBT / LBT CULTURE 45 /31 80/ 86 
MAC MOHAN
64
 30 GHBT CULTURE 75 30 
 
GHBT= Glucose hydrogen breath test, BABT= Bile acid breath test, XBT= Xylose breath test 
and LBT= Lactulose breath test 
 
Thus SIBO is not uncommon in chronic pancreatitis and seen in 1/3
rd
 of patients. GHBT can be 
used for diagnosis of SIBO in these patients. 
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1. SIBO was not uncommon in patients with chronic pancreatitis. 
2.  SIBO was diagnosed in 1/3rd of patients with chronic pancreatitis. 
3. GHBT can be used for diagnosis of SIBO and with a sensitivity of 62% and a specificity 
of 92% respectively. 
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STUDY NUMBER: 
                
 PROFORMA FOR CHRONIC PANCREATITIS 
 
NAME AGE SEX OCCUPATION 
    
 
RESIDENCE BMI SOCIOECONOMIC 
STATUS 
 
    
 
ALCOHOL/ NON ALCOHOL 
DIABETIC/ NON DIABETIC 
SYMPTOMS 
DYSPEPSIA PAIN BLOATING REFLUX  
     
 
SIGNS 
MALNUTRITION ABDOMINAL 
MASS 
SYSTEMIC 
FINDINGS 
MISC 
    
 
SCORE:  
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LABS AND OTHER INVESTIGATIONS 
 
BLOOD: CBC 
                LFT 
                OTHERS  
 
PANCREATITIS WORK UP 
IMAGING: TYPE OF STUDY – CECT ABDOMEN/ US ABDOMEN 
MPD  
GLAND  
PARENCHYMA  
CAVITY  
HEAD/BODY  
COMPLICATIONS  
 
BLOOD: VITAMIN B 12/FA - 
                VITAMIN D - 
72 HR STOOL FAT: 
EUS / ERCP: 
SCORE: 
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GLUCOSE HYDROGEN BREATH TEST 
0 MIN 15 30 45 60 75 90 120 150 180 
          
 
JEJUNAL ASPIRATE 
                                                     ORGANISMS 
 AEROBIC ANAEROBIC 
CFU   
 
 
 
S. No Name Age Sex MRD BMI SES RESI OCC ETIOLOGY DIABETES FAMILY PAIN
1 pr 28 m 15.6 low wb mech alc diab nil occ
2 bs 48 f 22 low wb hw na diab nil mod
3 lkb 45 m 21 low wb lab alc non nil sev
4 d.r 20 f 20.8 mid tn nur na non nil occ
5 hm 36 m 16.4 low ban lab na non nil sev
6 ss 40 m 15 low wb far alc diab nil sev
7 sk 26 f 23.4 low wb hw na non nil mod
8 sm 25 m 23 low wb far na non nil occ
9 br 49 f 19 low tn hw na diab nil occ
10 mmq 36 m 18 mid ban pvt na diab nil occ
11 ab 28 m 16 low pvt na diab nil occ
12 emr 30 m 17.8 low ban far na diab nil occ
13 rcb 30 m 21 mid wb pvt na non nil occ
14 vm 35 m 21 low ap lab alc non nil occ
15 mg 42 m 20.1 low wb lab alc non nil occ
16 vr 40 m 21.7 upp tn en alc diab nil occ
17 ac 20 m 21 mid wb stu na non nil mod
18 BKD 26 M 20 low wb pvt na diab nil NIL
19 mm 28 m 19 low wb lab na non nil
20 uk 28 f 22 low tn u na diab nil occ
21 nn 27 f 21 low ap pvt na non nil mod
22 ks 33 f 22 mid wb hw na diab nil mild
23 mzh 40 m 19.5 mid ban g na non nil mild
24 bd 21 m 15.6 low wb far na non nil occ
25 ns 28 m 18.7 mid ap pvt na non nil mod
26 rd 40 m 19 low tn lab na non nil occ
27 ckm 35 m 18.9 low wb pvt alc non nil occ
28 ak 35 f 16 mid wb pvt na non nil occ
29 aan 47 m 23 mid tn govt alc non nil NIL
30 sna 24 m 17.5 low wb pvt na non nil occ
31 snd 45 m 18.3 mid wb pvt alc non nil NIL
32 ra 21 m 16.5 low wb stu na non nil occ
33 knp 32 m 21 low wb lab na non nil mild
34 kal 21 f 15.6 low tn hw na non nil mod
35 sm 35 m 20 low wb lab alc non nil occ
36 sd 55 m 23 low chg lab alc diab nil mod
37 sk 23 m 24 low wb lab na non nil NIL
38 kkn 55 m 21 low nep retir na diab nil mild
39 ask 25 f 20 low wb hw na diab nil mild
40 skd 34 m 21 low wb lab alc non nil mod
41 mm 45 m 21 low wb lab alc non nil mod
42 sum 18 f 22 low wb stu na diab nil mild
43 dbp 45 m 21 low chg lab alc non nil mild
44 as.ch 54 m 22 low wb bus alc non nil NIL
45 kjm 43 m 23 low ban bus na diab nil NIL
46 ckm 26 m 21 low wb lab na non nil NIL
47 anb 23 m 19 low wb lab na diab nil NIL
48 shu.s 19 m 17 low wb stu na non nil NIL
DYSPEPSIA STEATOR MALNUTR Hb ALBUMIN SAP B12 FA STOOL IMAGING GHBT JEJ ASP
pos neg 13 4.9 132 1214 10 55 4 neg neg
pos neg nil 12 4.9 97 25 3 pos pos
pos neg nil 13 5 83 450 7.5 26 4 neg neg
pos neg nil 12 4.7 66 156 7.5 19.6 3 neg neg
pos pos pos 10 3.6 306 448 6.1 24 3 pos pos
pos neg pos 12 4.4 284 364 13 nd 3 neg neg
pos neg nil 12 4.7 91 566 8.6 15 2 neg neg
pos neg nil 13 5 27 622 8.7 23 eus neg neg
pos neg pos 11 3.9 1074 10 63 2 pos neg
pos pos nil 13 4.7 92 16 4 neg neg
pos neg pos 9.7 4.6 139 370 15 32.2 4 neg neg
pos pos nil 11 4.2 169 32.6 3 neg neg
pos neg nil 12 4 140 322 9.3 nd 1 neg neg
pos neg nil 14 4.8 206 29.4 4 pos pos
pos neg pos 11 4.1 69 331 7.4 nd 4 neg neg
pos neg nil 13 4.7 61 466 4.2 11.3 4 neg neg
pos neg nil 15 5 75 263 5 11 2 neg neg
pos neg nil 241 5 3 neg neg
14 5 104 11.2 2 pos pos
pos neg nil 12 4.6 313 4.4 12 2 neg pos
pos neg nil 7 929 4 14 3 pos pos
pos neg nil 1030 19 11 3 neg pos
pos neg pos 12 4.6 296 7 2 neg neg
n neg pos 15 4.9 161 6 16.7 4 pos pos
pos neg pos 14 5 144 3.6 nd 3 neg pos
neg neg nil 13 4.5 512 512 11 nd 2 neg neg
pos neg pos 13 4.6 57 674 8 25 2 neg neg
pos neg pos 13 4.3 233 10 20.6 2 neg neg
pos neg nil 14 4.5 312 312 5 nd 1 neg pos
pos neg pos 11 5 1096 10 nd 2 pos pos
neg pos pos 11 4.7 52 306 10 66.9 3 neg neg
pos neg pos 13 4.9 235 9.7 23 2 neg neg
pos neg nil 13 4.5 65 169 5.6 12.3 2 neg neg
pos neg nil 13 4 88 317 5 21 3 neg neg
pos neg nil 13 4 212 14 23.6 5 neg neg
pos pos pos 11 3.2 64 560 13 21 4 neg neg
neg neg nil 13 4.8 94 731 5.1 5 pos neg
pos neg pos 13 3.8 79 714 14 79.7 5 neg neg
pos neg nil 13 4.8 88 463 9 52.4 6 pos pos
pos neg pos 13 4.9 92 290 6.8 5 pos neg
pos neg nil 13 5 107 654 17 23 5 pos pos
pos neg nil 12 4 147 481 9.8 22 5 neg neg
pos neg nil neg neg
pos neg nil 14 5 335 5.2 23 4 neg neg
pos neg 13 5 99 999 20 58 5 neg neg
pos neg nil 15 4 60 653 10 23 neg pos
pos neg nil 13 4 61 674 7.9 23 6 neg pos
pos pos nil 8 3 89 221 5.6 5 pos pos
